EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually, February 11-12, 2025. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat on Tuesday, February 11, 2025 at 3:20 PM ET. The presentation can be assessed by visiting https ...

XOMA Royalty (XOMA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors o ...

XOMA Royalty (XOMA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.36%. A quarter ago, it was expected that this drug developer would post a loss of $0.26 per share when it actually produced a loss of $0.28, delivering a surprise of -7.69%.Over the last four quarters, the company has surp ...

Exhibit 99.1 XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio of 60-plus licensed early-stage assets across approximately 30 partners Cash receipts totaled $9.9 million in the third quarter, and $42.3 million for the first nine months of 2024 EMERYVILLE, Calif. – N ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the transition period from __________to__________ Commission File Number: 001-39801 XOMA Royalty Corporation (Exact name of Registrant as specified in its charter) Delaware 52-2154066 ...

XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now holds over 100 assets ranging from revenue-generating commercial therapeutics to pre-clinical programs EMERYVILLE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation to acquire a 50 percent economic interest in all future milesto ...

XOMA Royalty Corporation (NASDAQ: XOMA ) is a biotechnology royalty aggregator that obtains milestone and royalty rights from investigational and commercial drugs. XOMA's business model is to provide nondilutive funding to biotech companies, allowing them to fund their research without My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens ...

XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, representing a turnover rate of 0.03% and a price fluctuation amplitude of 3.79%. Financial reports indicate that XOMA achieved a revenue of $11.09 million, net profit of $15.99 million, and earnings per share of $0.88. The gross profit stood at $11.08 million, with a price-to-earnings ratio of -11.85. Within the indust ...

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA's 8.375% Series B Cu ...

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following September 2024 investor conferences: H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will present a corporate overview on Monday, September 9, 2024, at 9:00 AM ET. ...